Emerging Strategies for More Cost-Effective Product Development in the NASH Indication

Publish Date:
March 15, 2017
Presenters:
Randy Anderson, PhD, SVP Scientific and Regulatory Affairs, Therapeutic Area Leader for Endocrinology & Metabolism

Chiltern’s Randy Anderson, PhD, therapeutic area leader for diseases of endocrinology and metabolism, explores new strategies and technologies for managing the complexity of nonalcoholic steatohepatitis (NASH) product studies while maintaining a cost-effective partnership with your CRO. This presentation was originally given at OCT West Coast in Burlingame, CA, February 22, 2017.

TO DOWNLOAD THE White Paper SUBMIT THE INFORMATION BELOW

Fields marked with an * are required